spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Janssen 

 HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Jun 2024
Halozyme Announces Roche's OCREVUS(R) SC with ENHANZE(R) Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 14 Jun 2024
TALVEY(R) (talquetamab-tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Feb 2024
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Oct 2023
Mozart Therapeutics Expands Executive Leadership Team with Appointments of Dr. Jason Chien, Chief Medical Officer, and Russ Hawkinson, Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Dec 2022
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 May 2022
Remix Therapeutics Closes $70 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 5 Apr 2022
MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Mar 2022
Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Dec 2021
OncoSec Announces Changes to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Dec 2021
Johnson & Johnson Appoints Senior Leaders to Executive Committee
Devices Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Nov 2021
Smith & Nephew Launches 'Turn-Key' Robotic-Assisted Surgical System; Designed to Quickly Augment the Orthopaedic Team's Skills Set for Greater Accuracy(1-3)¥, Improved Outcomes(4), and Potentially an Immediate Scalable Solution to NHS
Devices Orthopaedic Surgery Product Launch
 HSMN NewsFeed - 12 Oct 2021
Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson To Retire, Effective December 31, 2021
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Oct 2021
Novavax Announces Leadership Appointment and Updates
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Sep 2021
Mirati Therapeutics Appoints David Meek as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Sep 2021
Sutro Biopharma Announces Expansion of Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Sep 2021
Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology
Biopharmaceutical Gastroenterology Personnel
 HSMN NewsFeed - 31 Aug 2021
Bactiguard recruits Chief Licensing Officer to accelerate growth
Devices Licensing Personnel
 HSMN NewsFeed - 12 Jul 2021
Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Jul 2021
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Jun 2021
Eisai Inc. Announces the Appointment of Dr. Andree Amelsberg as Vice President, U.S. Medical Affairs, Oncology Business Group
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Jun 2021
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE(R) drug delivery technology to enable development of "ultra-long-acting" medicines for HIV
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 1 Jun 2021
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Mar 2021
Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Feb 2021
Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
Biopharmaceuticals
 HSMN NewsFeed - 4 Feb 2021
Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Oct 2020
Yew Looi Liew Named President of U.S. Human Pharma for Boehringer Ingelheim Pharmaceuticals, Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Oct 2020
Armata Pharmaceuticals Appoints Mina Pastagia, MD, MS as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Oct 2020
Johnson & Johnson Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen's COVID-19 Vaccine Candidate
Biopharmaceuticals
 HSMN NewsFeed - 6 Oct 2020
Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE(R) Technology
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 23 Sep 2020
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate
Biopharmaceuticals
 HSMN NewsFeed - 9 Sep 2020
Phosplatin Therapeutics Announces Two Leadership Appointments
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Aug 2020
Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Aug 2020
Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine
Biopharmaceuticals
 HSMN NewsFeed - 30 Jul 2020
Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies
Biopharmaceuticals
 HSMN NewsFeed - 17 Jul 2020
Interim Six-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosa
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 14 Jul 2020
TREMFYA(R) (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Jun 2020
Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 10 Jun 2020
Akero Therapeutics Appoints Tom Heyman to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Mar 2020
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use
Biopharmaceuticals
 HSMN NewsFeed - 9 Mar 2020
Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 13 Jan 2020
Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular Degeneration (AMD) and Diabetic Macular Edema
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 8 Nov 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Nov 2019
Halozyme Announces Actions To Focus Strategy On ENHANZE(R) Drug Delivery Technology
Biopharmaceuticals Drug Delivery Reduction in Force
 HSMN NewsFeed - 4 Oct 2019
Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 22 Jul 2019
Geron Enhances Oncology Expertise to Advance Corporate Objectives
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Jul 2019
Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX(R) Utilizing ENHANZE(R) Technology
Biopharmaceuticals Oncology Drug Delivery Regulatory
 HSMN NewsFeed - 9 Jul 2019
BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jun 2019
DayTwo Secures $31 Million In Series B Financing To Scale Microbiome Research Platform To Address Chronic Health Conditions
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Jun 2019
Janssen reports top-line Phase 3 results for TREMFYA(R) (guselkumab) in adults with active psoriatic arthritis
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2019
Halozyme Announces argenx Has Selected Second Target Under ENHANZE(R) Technology Collaboration And License Agreement
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 6 May 2019
Halozyme Names Dr. Alison A. Armour As Senior Vice President of Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Apr 2019
Lannett To Launch Generic Concerta(R), AB-rated Methylphenidate Hydrochloride ER Tablets
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 25 Apr 2019
DURECT Appoints Two New Board Members
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 2 Apr 2019
Provention Bio Announces Key Additions to its Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Feb 2019
U.S. FDA Approves DARZALEX(R) (daratumumab) Split-Dosing Regimen
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Feb 2019
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE(R) Technology
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 28 Jan 2019
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Jan 2019
Johnson & Johnson Announces Research Study with Apple Watch to Help Improve AFib Outcomes Including Stroke Prevention
Devices Cardiology Monitoring
 HSMN NewsFeed - 7 Jan 2019
Protagonist Therapeutics Appoints Suneel K. Gupta, Ph.D., as Executive Vice President of Clinical Operations and Pharmacology
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Dec 2018
Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 30 Oct 2018
U.S. FDA Approves INVOKANA(R) (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
Biopharmaceuticals Endocrinology Cardiology FDA
 HSMN NewsFeed - 17 Oct 2018
Adam Hacker, PhD Joins Autolus as Senior Vice President for Regulatory Affairs and Quality
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Oct 2018
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Oct 2018
OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of Investigational New Drug Application to Evaluate Tedopi(R) in Combination with Nivolumab in Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Sep 2018
Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin(R)) In Canada
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Sep 2018
Halozyme Appoints Bernadette Connaughton To Board Of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Sep 2018
Halozyme Names Benjamin Hickey As Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Aug 2018
AbbVie Announces IMBRUVICA(R) (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Aug 2018
Janssen Announces Results from MARINER and COMMANDER HF Studies
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 1 Aug 2018
IGM Biosciences Appoints Daniel S. Chen, M.D., Ph.D., as Chief Medical Officer; Names William Strohl, Ph.D., to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Jul 2018
PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 26 Jul 2018
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
Biopharmaceuticals Oncology Drug Delivery
 HSMN NewsFeed - 17 Jul 2018
Spruce Biosciences Appoints David Moriarty, Ph.D., as Vice President of Development Operations
Biopharmaceuticals Endocrinology Personnel
 HSMN NewsFeed - 11 Jul 2018
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 25 Jun 2018
IMBRUVICA(R) (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Jun 2018
Lannett Receives FDA Approval For Levofloxacin Oral Solution; Imminent Launch Anticipated
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 30 May 2018
Legend Announces FDA Clearance of IND Application on CAR-T Immuno-cell Therapy for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 May 2018
IMBRUVICA(R) (ibrutinib) Plus GAZYVA(R) (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2018
Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 8 May 2018
Pliant Therapeutics Appoints Hoyoung Huh as Chairman and Éric Lefebvre as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Apr 2018
Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT(R) (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Apr 2018
Improving Cardiology Care: BIOTRONIK US to Distribute Aziyo ECM Envelopes
Devices Cardiology Distribution
 HSMN NewsFeed - 15 Mar 2018
Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer
Biopharmaceuticals Oncology Urology FDA
 HSMN NewsFeed - 8 Feb 2018
ZYTIGA(R) (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jan 2018
Enterome Raises €32 Million ($38.5 Million) in a Series D Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 14 Dec 2017
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 12 Dec 2017
DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Dec 2017
INVOKANA(R) (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease
Biopharmaceuticals Nephrology
 HSMN NewsFeed - 30 Oct 2017
FDA Approves New 10 mg Dosing for XARELTO(R) (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Oct 2017
Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Sep 2017
DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2017
Janssen Receives CHMP Positive Opinion for Guselkumab Recommending Approval for the Treatment of Moderate to Severe Plaque Psoriasis in the European Union
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 14 Sep 2017
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 7 Sep 2017
Vividion Therapeutics Appoints Diego Miralles, M.D., Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Sep 2017
Pulmatrix Licenses Inhaled COPD Drug PUR0200 to Vectura Group plc
Biopharmaceuticals Licensing
 HSMN NewsFeed - 6 Sep 2017
Actelion Receives FDA Approval Of TRACLEER(R) (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Aug 2017
ESC Congress 2017: BIOTRONIK's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Aug 2017
Getinge announces full U.S. availability of Pulsar(R)-18 self-expanding stent from BIOTRONIK for patients with peripheral artery disease
Devices Interventional Product Launch
 HSMN NewsFeed - 21 Aug 2017
BIOTRONIK US Launches Smallest MR Conditional Quadripolar Cardiac Resynchronization Therapy Pacemaker
Devices Cardiology FDA Product Launch
 HSMN NewsFeed - 14 Aug 2017
Synthorx Appoints Marcos Milla, Ph.D. as Senior Vice President of Research
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jul 2017
Cochlear Introduces the World's First Made-for-iPhone Cochlear Implant Sound Processor
Devices Product Launch
 HSMN NewsFeed - 11 Jul 2017
Enterome and Nestlé Health Science Launch New Diagnostics Company
Diagnostics
 HSMN NewsFeed - 3 Jul 2017
BIOTRONIK US Announces Pivotal Trial Results of the Pulsar-18 Stent with 4-French Delivery System
Devices Interventional
 HSMN NewsFeed - 26 Jun 2017
Provention Bio, Inc. Secures $28.4 Million Founding Financing to Fund Development Targeting the Interception and Prevention of Immune-Mediated Disease
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Jun 2017
Johnson & Johnson Announces Completion of Acquisition of Actelion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Jun 2017
Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jun 2017
New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2017
Janssen Enters Into Worldwide Exclusive License and Collaboration Agreement With Protagonist Therapeutics, Inc. for Oral Interleukin-23 Receptor Antagonist Drug Candidate for the Treatment of Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 11 May 2017
Xencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Apr 2017
BIOTRONIK Introduces Smallest MR Conditional Defibrillator Lead in the US
Devices Cardiology Radiology Product Launch
 HSMN NewsFeed - 17 Apr 2017
Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Feb 2017
CHMP Issues Positive Opinion Recommending DARZALEX(R) (daratumumab) for Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Feb 2017
Genmab Appoints Judith Klimovsky, MD, as Chief Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Jan 2017
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Jan 2017
Ascletis Raises US$100 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Dec 2016
Janssen Submits Application Seeking FDA Approval of STELARA(R) (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 14 Dec 2016
Health Canada approves STELARA(R) for the treatment of adults with moderately to severely active Crohn's disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 28 Nov 2016
Addex Appoints Biopharmaceutical Industry Veteran, Roger G. Mills, M.D., as Chief Medical Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 22 Nov 2016
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Nov 2016
Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-derived Biomarkers, Drug Targets and Bioactive Molecules
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 3 Nov 2016
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Nov 2016
Enterome Appoints Christophe Bonny as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Oct 2016
Launch of Carrick Therapeutics Signals New Approach to Cancer Therapies
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 28 Sep 2016
Assembly Biosciences Announces Key Additions to Microbiome Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Sep 2016
AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA(R)) for Treatment of Marginal Zone Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Sep 2016
U.S. FDA Approves INVOKAMET(R) XR (Canagliflozin / Metformin Hydrochloride Extended-Release) for the Treatment of Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 7 Sep 2016
Marinus Appoints Seth H.Z. Fischer to its Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 15 Aug 2016
Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 26 Jul 2016
Janssen Announces Clinical Collaboration with Bristol-Myers Squibb to Evaluate Immuno-oncology Combination in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jul 2016
David Meek appointed as Chief Executive Officer of Ipsen
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jun 2016
AbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration (FDA) for Ibrutinib (IMBRUVICA(R)) for Chronic Graft-Versus-Host-Disease (cGVHD), a Rare Condition with Limited Treatment Options
Biopharmaceuticals
 HSMN NewsFeed - 30 May 2016
FLIXABI(R), Biogen’s Infliximab Biosimilar Referencing Remicade(R), Approved in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 May 2016
U.S. FDA Expands IMBRUVICA(R) (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Apr 2016
Enterome Raises EUR14.5 Million in Series C Financing Round
Biopharmaceuticals Gastroenterology Venture Capital
 HSMN NewsFeed - 6 Apr 2016
Janssen Enters Worldwide Collaboration and License Agreement with TESARO, Inc., for Niraparib in Prostate Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 18 Mar 2016
STELARA(R) Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 24 Feb 2016
Forty Seven Inc. Completes $75M Series A Financing and Licenses Technology from Stanford University to Advance Next Generation Immuno-Oncology Programs
Biopharmaceuticals Oncology Venture Capital Licensing
 HSMN NewsFeed - 4 Feb 2016
Cerapedics Announces Publication of Results from Pivotal IDE Clinical Trial of i-FACTOR(TM) Bone Graft in the Cervical Spine
Devices Orthopaedic Neurosurgery
 HSMN NewsFeed - 3 Feb 2016
Maquet Medical Systems USA, A Getinge Group Company Announces Partnership with BIOTRONIK to Distribute Endovascular Medical Devices in United States
Devices Interventional Distribution
 HSMN NewsFeed - 21 Jan 2016
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 4 Jan 2016
Scholar Rock Announces $36 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 21 Dec 2015
Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly
Biopharmaceuticals Licensing
 HSMN NewsFeed - 17 Nov 2015
Mylan Launches Generic AXERT(R) Tablets
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 13 Nov 2015
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Oct 2015
Mirna Therapeutics Appoints Dr. Miguel Barbosa as Executive Vice President and Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Oct 2015
Head Janssen Neuroscientist Appointed to Scientific Advisory Board of Global Dementia Discovery Fund
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 16 Oct 2015
Johnson & Johnson Announces Start of Clinical Trial of Ebola Vaccine Regimen in Sierra Leone
Biopharmaceuticals
 HSMN NewsFeed - 15 Sep 2015
Molecular Response Appoints the Former Head of Translational Medicine Oncology at MedImmune/AstraZeneca, Brett Hall, Ph.D., as Chief Executive Officer
Diagnostics Personnel
 HSMN NewsFeed - 15 Sep 2015
Depomed Files New Patent Infringement Lawsuit Against NUCYNTA(R) ER ANDA Filer
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 2 Sep 2015
Ascletis Secures US$35 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 31 Jul 2015
Xencor Appoints Yujiro S. Hata to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jul 2015
Synergy Pharmaceuticals Appoints Troy Hamilton as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Apr 2015
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Mar 2015
Janssen Acquires XO1 Limited
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 13 Mar 2015
Minerva Neurosciences Announces $31 Million Financing
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 3 Feb 2015
U.S. FDA Grants Priority Review for YONDELIS(R) (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jan 2015
Aduro Biotech Closes $51.4 Million Series D Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 17 Dec 2014
Inovio Pharmaceuticals Appoints Zane Yang, M.D. Vice President, Clinical Development, Oncology
Biopharmaceuticlas Oncology Personnel
 HSMN NewsFeed - 22 Sep 2014
Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Sep 2014
Evotec Takes Legal Steps Against Andromeda Biotech, Ltd.
Biopharmaceuticals Litigation
 HSMN NewsFeed - 4 Sep 2014
Johnson & Johnson Responds to Ebola Crisis With Commitment to Accelerate Vaccine Program in Collaboration With the US National Institutes of Health (NIH) and Provide Humanitarian Relief Aid
Biopharmaceuticals
 HSMN NewsFeed - 25 Jul 2014
European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA(R) (ibrutinib) for Treatment of Two Blood Cancers
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Jun 2014
Bioventus Announces U.S. Debut of Feature-Rich New EXOGEN(R) Device
Devices Orthopaedic Product Launch
 HSMN NewsFeed - 29 May 2014
Aduro Announces License Agreement with Johnson & Johnson Innovation for Novel Immunotherapies for Prostate Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 14 May 2014
Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 May 2014
SAGE Therapeutics Appoints Thomas D. Anderson as Chief Commercial Strategy Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Mar 2014
Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Mar 2014
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jan 2014
Janssen Announces New Group Targeting Unmet Global Health Needs
Biopharmaceuticals
 HSMN NewsFeed - 13 Jan 2014
Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis
Biopharmaceuticals
 HSMN NewsFeed - 7 Jan 2014
Cempra, Inc. Names David Moore as Chief Commercial Officer to Manage Commercial Development and Launch of Solithromycin and Taksta(TM)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jan 2014
Fibrocell Science Appoints Robert Sheroff, Vice President of Technical Operations
Biopharmaceuticals Regenerative Medicine Personnel
 HSMN NewsFeed - 3 Jan 2014
NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara(R) in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Dec 2013
Myriad Genetics Announces Cancer Research Collaboration With Janssen
Diagnostics Oncology
 HSMN NewsFeed - 29 Nov 2013
New Data Show Efficacy, Safety and Tolerability of Xeplion(R) in Patients with Schizophrenia at Various Stages of the Disease
Biopharmaceuticals
 HSMN NewsFeed - 20 Nov 2013
Vertex Sells INCIVO(R) Product Royalty Rights for $152 Million
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 6 Nov 2013
Coronado Biosciences Announces Personnel Realignment, Including Appointment of Kevin Horgan, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Nov 2013
Ferring Pharmaceuticals Appoints Alex Chang Senior Vice President, Asia Pacific
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Oct 2013
Arcturus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Sep 2013
Otsuka Pharmaceutical to Acquire Astex Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Sep 2013
GSK’s MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Melanoma Misses First Co-Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Aug 2013
European Commission Approves VELCADE(R) as a Frontline Induction Therapy before Stem Cell Transplantation
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Jul 2013
Ligand Receives Orphan Designation for Captisol-Enabled(TM) Topiramate Injection
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 17 Jun 2013
Siemens to Create Companion Diagnostic Test for In-Development Janssen Heart Failure Drug
Diagnostics Personalized Medicine Cardiology
 HSMN NewsFeed - 17 Jun 2013
Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 17 Jun 2013
NGM Biopharmaceuticals and MedImmune, AstraZeneca's Biologics Arm, Announce Agreement to Discover and Develop Therapies for Diabetes and Obesity
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 5 Jun 2013
Johnson & Johnson Innovation Announces Opening of the California Innovation Center
Devices
 HSMN NewsFeed - 3 Jun 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 15 May 2013
Tokai Pharmaceuticals Announces $35.5 Million Series E Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 7 May 2013
Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 1 May 2013
Ultragenyx Appoints Eric Yuen, MD as Chief Medical Officer and Senior Vice President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Apr 2013
Lantheus Medical Imaging Realigns Executive Leadership Team
Biopharmaceuticals Radiology Personnel
 HSMN NewsFeed - 8 Apr 2013
Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Mar 2013
SciClone Appoints Hong Zhao as Chief Executive Officer, China Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Mar 2013
Intercept Pharmaceuticals Appoints Daniel Regan as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jan 2013
European Commission Approves PREZISTA(R) (darunavir) 800 mg Tablet Once a Day Reducing the Number of Pills Taken by People Living With HIV
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 31 Dec 2012
FDA Grants Accelerated Approval for SIRTURO(TM) (bedaquiline) as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Dec 2012
FDA Approves Gattex(R) (teduglutide [rDNA Origin]) for Injection for the Treatment of Adult Short Bowel Syndrome
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 19 Nov 2012
ZYTIGA(R) Receives Positive Regulatory Recommendation in the European Union for Treatment of Metastatic Castration-Resistant Prostate Cancer before Chemotherapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Nov 2012
Tris Pharma Appoints New Vice President of Business Development
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 28 Sep 2012
PTC Therapeutics Appoints Jerome B. Zeldis, M.D., Ph.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Sep 2012
Impax Laboratories Announces Settlement of Litigation Relating to CONCERTA(R)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 5 Sep 2012
ImmuNext Enters into a Strategic Partnership with Janssen to Develop Novel Immunotherapies for the Treatment of Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2012
FORMA Therapeutics Appoints Dr. Rob Sarisky to Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Sep 2012
Two New Executives Join VaxInnate Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Sep 2012
Revestive(R) (teduglutide) Receives European Marketing Authorization for the Treatment of Adults with Short Bowel Syndrome (SBS)
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 30 Aug 2012
Genmab Enters Worldwide Agreement With Janssen for Daratumumab
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 29 Aug 2012
U.S. FDA Grants Priority Review of ZYTIGA(R) (abiraterone acetate) sNDA for Treatment of Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Aug 2012
Depomed Licenses Acuform(R) Patents to Janssen Pharmaceuticals, Inc.
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 22 Jun 2012
Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive(R)) for Patients with Short Bowel Syndrome
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 15 Jun 2012
ViaCyte Appoints Dr. Paul Laikind Chief Executive Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 15 May 2012
New Executive Vice President Commercial Appointed
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 May 2012
Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA for XARELTO(R) (rivaroxaban) to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 26 Mar 2012
Delcath Expands Global Marketing Team With Key Pharma Oncology Hire
Devices Drug Delivery Oncology Personnel
 HSMN NewsFeed - 29 Feb 2012
NPS Pharmaceuticals Appoints Georges Gemayel, Ph.D., to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jan 2012
Remicade(R) (Infliximab) Receives Positive Opinion From CHMP In Europe for Treatment of Ulcerative Colitis in Pediatric Patients
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 10 Jan 2012
Shire Acquires US Rights to Resolor(R) (prucalopride)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 1 Nov 2011
FDA Approves Addition of Sustained Overall Survival Advantage (5-year follow-up) to Label for VELCADE(R) in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Oct 2011
Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Sep 2011
FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 6 Sep 2011
Savient Announces the Election of William F. Owen, Jr., M.D. and David Y. Norton to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Aug 2011
NUCYNTA(R) ER (Tapentadol Extended-Release Tablets) Receives FDA Approval for the Management of Moderate to Severe Chronic Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Aug 2011
Publication of BIOTRONIK Home-CARE Clinical Study Results Confirms Potential New Approach for Earlier Detection of Cardiovascular Events
Devices Cardiology Monitoring
 HSMN NewsFeed - 1 Aug 2011
Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jul 2011
Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
Biopharmaceuticals
 HSMN NewsFeed - 30 Jun 2011
Sheila Gujrathi, M.D. Named Chief Medical Officer of Receptos
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jun 2011
BIOTRONIK Launches Lumax 540 VR-T DX, The World’s Only Single-Chamber ICD With Complete Atrial Diagnostics
Devices Cardiology
 HSMN NewsFeed - 23 Jun 2011
Jules A. Müsing Joins iBio’s Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 May 2011
FDA Approves INCIVEK(TM) (telaprevir) for People with Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 May 2011
Alkermes to Merge with Elan Drug Technologies to Create Alkermes plc
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 26 Apr 2011
Diamyd Medical Replaces CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Mar 2011
New BIOTRONIK AlCath Flux eXtra Gold Is Launched in Europe
Devices Cardiology
 HSMN NewsFeed - 11 Feb 2011
Simcere Pharmaceutical Group Appoints Industry Veteran Mr. Hong Zhao as Executive Vice President of Sales and Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Feb 2011
BIOTRONIK Introduces New Unique Reliaty Pacing System Analyzer
Devices Cardiology
 HSMN NewsFeed - 25 Jan 2011
Labopharm Announces Executive Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jan 2011
Angelini Labopharm Confirms Appointment of Mary Anne Heino as President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jan 2011
Orexo and Invida Jointly Announce Agreement for Abstral(TM) in Asia Pacific
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 13 Jan 2011
Anders Lundström to Be the New CEO of Orexo
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jan 2011
Orexo: FDA Approval For Abstral (Fentanyl) Sublingual Tablets - US Launch Planned For Q1 2011
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Dec 2010
Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee
Biopharmaceuticals Devices Personnel
 HSMN NewsFeed - 1 Dec 2010
BIOTRONIK Expands Range of State-of-the-Art Pacing Therapies with the European Approval of the New Estella and Effecta Pacemaker Series
Devices Cardiology Regulatory
 HSMN NewsFeed - 12 Nov 2010
Vanda Pharmaceuticals Appoints Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Oct 2010
BIOTRONIK Releases New Heart Failure Diagnostic Method to Support the Monitoring of Patients with Heart Failure
Devices Cardiology Monitoring
 HSMN NewsFeed - 11 Oct 2010
Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Oct 2010
New Data Demonstrate Treatment With STELARA(R) (Black Triangle Drug) (ustekinumab) Results in Sustained Improvements in Psoriasis Severity and Quality of Life up to Three Years
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 4 Oct 2010
FDA Issues Complete Response Letter to Johnson & Johnson Pharmaceutical Research & Development Regarding New Drug Application for Tapentadol Extended Release
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Sep 2010
Inspire Names Robert Savel as Senior Vice President and Chief Technical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jun 2010
Eisai Announces Results of Phase III Study of Dacogen(R) (Decitabine) for Injection in Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jun 2010
Lonnel Coats Appointed President & Chief Executive Officer of Eisai Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 May 2010
STELARA(TM) Significantly Improves Symptoms of Depression, Anxiety and Health-Related Quality of Life in Patients With Moderate to Severe Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 10 May 2010
Takeda to Co-Promote VELCADE(R) (bortezomib) for Injection in Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Apr 2010
BIOTRONIK adds New "Reocor" External Pacemaker to its High-Quality Product Portfolio
Devices Cardiology
 HSMN NewsFeed - 13 Apr 2010
FDA Approves New Drug Application for PANCREAZE(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Feb 2010
Lantheus Medical Imaging, Inc. Announces Appointment of Robert A. Spurr as Vice President, Sales and Marketing
Biopharmaceuticals Radiology Personnel
 HSMN NewsFeed - 1 Feb 2010
Human Genome Sciences Names Scott Habig Vice President, Sales
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jan 2010
BIOTRONIK and Endosense Sign International Exclusive Distribution Partnership
Devices Cardiology Distribution
 HSMN NewsFeed - 14 Jan 2010
STELARA(TM) (ustekinumab) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 4 Jan 2010
FDA Approves Addition of Sustained Overall Survival Benefit to Label for VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Dec 2009
VELCADE(R) (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up to 88 Percent in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Dec 2009
New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Nov 2009
Arrowhead Subsidiary Calando Pharmaceuticals Expands Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 15 Oct 2009
BIOTRONIK Home Monitoring(R) Receives Industry's First Approval to Safely Replace Hospital Visits for Cardiac Device Follow-Ups
Devices Cardiology Monitoring Regulatory
 HSMN NewsFeed - 6 Oct 2009
SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Sep 2009
Johnson & Johnson and Crucell Announce Strategic Collaboration to Develop Innovative Products, Including Therapies for Influenza Prevention and Treatment
Biopharmaceuticals
 HSMN NewsFeed - 23 Sep 2009
Janssen-Cilag's STELARA(R) (Black Triangle Drug) (ustekinumab) Approved by NICE for the Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 18 Sep 2009
FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE(R) (bortezomib) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Sep 2009
Elan Cures Breach of Tysabri(R) Collaboration Agreement and Amends Terms of Transaction with Johnson & Johnson
Biopharmaceuticals Litigation
 HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Jul 2009
Teva Provides Update on Generic Ortho Tri-Cyclen(R) Lo
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 1 Jul 2009
Teva Announces Approval and Launch of Tri-Lo Sprintec Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 26 Jun 2009
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Jun 2009
Paulo F. Costa Joins MacroGenics Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jun 2009
BIOTRONIK: First and Only Pacemaker Platform with Fully Integrated Wireless Remote Follow-up Capabilities Introduced at Europace Congress in Berlin
Devices Cardiology Regulatory
 HSMN NewsFeed - 17 Jun 2009
Neuromed Announces Sale of U.S. Rights to Drug Candidate Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) to Mallinckrodt
Biopharmaceuticals
 HSMN NewsFeed - 21 May 2009
Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 18 May 2009
FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Apr 2009
RISPERDAL CONSTA Approved in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Apr 2009
SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Apr 2009
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Topamax(R) Tablets
Biopharmaceuticals Generics
 HSMN NewsFeed - 30 Mar 2009
Global Launch of the new BIOTRONIK Home Monitoring(R)
Devices Cardiology Monitoring
 HSMN NewsFeed - 27 Mar 2009
Zydus Pharmaceuticals (USA) Inc. Announces FDA Final Approval for the Generic Version of Topamax(R) Tablets
Biopharmaceuticals Neurology FDA Generics
 HSMN NewsFeed - 23 Mar 2009
Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 23 Mar 2009
Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial
Biopharmaceuticals Pain Management
 HSMN NewsFeed - 24 Feb 2009
Basilea Pharmaceutica files claims against Johnson&Johnson over its handling of ceftobiprole (ZEFTERA(TM)/Zevtera(TM)) clinical studies
Biopharmaceuticals Litigation
 HSMN NewsFeed - 24 Feb 2009
CHMP delays European Commission decision process to approve ZEVTERA(TM)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Feb 2009
BIOTRONIK Announces CE Mark and First Successful Clinical Case with TRIGNUM Flux Magnetic Irrigated Gold Tip Catheter
Devices Cardiology Regulatory
 HSMN NewsFeed - 10 Feb 2009
FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Feb 2009
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jan 2009
Teva Announces Approval of Generic Risperdal(R) Oral Solution
Biopharmacueticals Generics FDA
 HSMN NewsFeed - 22 Jan 2009
New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 31 Dec 2008
PriCara(R) Recalls 50 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches
Biopharmaceuticals Drug Delivery Product Recall
 HSMN NewsFeed - 16 Dec 2008
Watson Pharmaceuticals Receives FDA Approval for Generic Razadyne(R) ER Capsules
Biopharmaceuticals Generics Neurology FDA
 HSMN NewsFeed - 27 Nov 2008
European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 21 Nov 2008
Zevtera(TM) (ceftobiprole medocaril), the novel anti-MRSA broad-spectrum antibiotic, receives a positive opinion from the CHMP
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Oct 2008
One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
Biopharmaceuticals
 HSMN NewsFeed - 24 Oct 2008
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 Oct 2008
One Year of GATTEX(TM) Therapy Safely Reduces Parenteral Nutrition Dependence for Patients with Short Bowel Syndrome
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 7 Oct 2008
Halcygen Successfully Completes First Pivotal Trial with SUBA-Itraconazole(tm)
Biopharmaceuticals
 HSMN NewsFeed - 26 Sep 2008
The New BIOTRONIK Home Monitoring(R) Approved in Europe
Devices Cardiology Monitoring Regulatory
 HSMN NewsFeed - 18 Sep 2008
Findings From Landmark Study Show Ustekinumab Demonstrated Superior Efficacy to Enbrel(R) (Etanercept) in Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 16 Sep 2008
Mylan Receives FDA Approval for Generic Version of Anti-Psychotic Risperdal(R)
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 8 Sep 2008
VELCADE(R) (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 Aug 2008
INTELENCE(TM) (Etravirine) Receives Marketing Authorisation in the European Union for HIV Combination Therapy
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 27 Aug 2008
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Aug 2008
Milestone Biosciences, LLC Further Strengthens Executive Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Aug 2008
FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Aug 2008
Alkermes Announces Approval of VIVITROL(R) for the Treatment of Alcohol Dependence in Russia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Jul 2008
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Rivaroxaban
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Jul 2008
FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 1 Jul 2008
Ikaria(R) Strengthens Research & Development Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2008
SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jun 2008
FDA Approves EVOLENCE(R), a New Generation Collagen-Based Facial Filler
Devices Dermatology FDA
 HSMN NewsFeed - 30 Jun 2008
Ceftobiprole, a new anti-MRSA broad-spectrum antibiotic, receives its first marketing authorization by Health Canada
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Jun 2008
Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals
 HSMN NewsFeed - 17 Jun 2008
FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 11 Jun 2008
Phase 3 Data Show Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Previously Treated with Anti-TNF Agents
Biopharmaceuticals
 HSMN NewsFeed - 11 Jun 2008
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 May 2008
Phase 3 GATTEX(TM) Results Presented at Annual Digestive Disease Week Congress Highlight Potential New Treatment in Short Bowel Syndrome
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 7 May 2008
Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
Biopharmaceuticals
 HSMN NewsFeed - 10 Apr 2008
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Mar 2008
Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 Mar 2008
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Feb 2008
Ophthalmic Imaging Systems Appoints Marc De Clerck to Serve on Board of Directors
Devices Ophthalmology Personnel
 HSMN NewsFeed - 27 Feb 2008
Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
Biopharmaceuticals
 HSMN NewsFeed - 27 Feb 2008
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
Biopharmaceuticals
 HSMN NewsFeed - 20 Feb 2008
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Feb 2008
IntraOp Medical Corporation Raises Additional Equity from New and Existing Investors
Devices Oncology
 HSMN NewsFeed - 4 Feb 2008
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 30 Jan 2008
FDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Jan 2008
SV Life Sciences Appoints Dr. Hamish Cameron as Venture Partner
Venture Capital Personnel
 HSMN NewsFeed - 7 Jan 2008
Alkermes Announces Agreement for the Commercialization of VIVITROL in Russia/CIS
Biopharmaceuticals
 HSMN NewsFeed - 3 Jan 2008
Akela Pharma licenses Fentanyl TAIFUN(R) to Janssen Pharmaceutica NV for Canada
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 2 Jan 2008
Biovail Announces Supply Agreement for Commercialization of Extended-Release Tramadol
Biopharmaceuticals Distribution
 HSMN NewsFeed - 21 Dec 2007
Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 18 Dec 2007
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 12 Dec 2007
INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 10 Dec 2007
VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2007
Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2007
Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2007
Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals FDA Regulatory
 HSMN NewsFeed - 2 Dec 2007
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Nov 2007
New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Nov 2007
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2007
New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms Of Ankylosing Spondylitis According to Phase 3 Study Findings
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2007
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
Biopharmaceuticals
 HSMN NewsFeed - 30 Oct 2007
NPS Pharmaceuticals Names Douglas N. Dobak Vice President of Regulatory Affairs and Drug Safety
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Oct 2007
Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Oct 2007
Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077
Biopharmaceuticals Pain Mangement FDA
 HSMN NewsFeed - 15 Oct 2007
FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 9 Oct 2007
Basilea Announces Positive Top-line Data from Phase III Study of Ceftobiprole in Hospital-Acquired Pneumonia
Biopharmaceuticals
 HSMN NewsFeed - 3 Oct 2007
Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 18 Sep 2007
New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 18 Sep 2007
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Sep 2007
Canadian Regulatory Authority has Accepted for Review New Drug Submission for Ceftobiprole
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Aug 2007
Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
Biopharmaceuticals Generics FDA Neurology
 HSMN NewsFeed - 24 Aug 2007
IntraOp Medical Raises Equity, Restructures Debt, Names New President /CEO and Appoints New Board of Directors
Devices Radiology Personnel
 HSMN NewsFeed - 22 Aug 2007
FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Aug 2007
Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
Biopharmaceuticals Generics FDA Drug Delivery
 HSMN NewsFeed - 15 Aug 2007
Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Aug 2007
NeurAxon Appoints Robert Medve, M.D., as Chief Medical and Regulatory Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Aug 2007
Neuromed Appoints Mario Orlando as Vice President of Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jul 2007
Basilea Announces Filing of New Drug Submission in Canada for Ceftobiprole
Biopharmaceuticals
 HSMN NewsFeed - 16 Jul 2007
Millennium Initiates Phase III Trial to Determine the Optimal VELCADE(R) (Bortezomib) for Injection Based Therapy in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jul 2007
New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 6 Jul 2007
TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 5 Jul 2007
New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 2 Jul 2007
VELCADE(R) (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2007
INVEGA(TM) Receives Marketing Authorization In European Union For Treatment Of Schizophrenia
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Jun 2007
FDA Issues Approvable Letter for RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Jun 2007
LAB International licenses Fentanyl TAIFUN(R) to Janssen Pharmaceutica NV for Europe
Biopharmaceuticals Licensing
 HSMN NewsFeed - 18 Jun 2007
Basilea Announces Submission of Marketing Authorization Application in Europe by Janssen-Cilag International NV for Ceftobiprole, a Novel Anti-MRSA Broad-spectrum Cephalosporin
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 Jun 2007
REMICADE(R) Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation
Biopharmaceuticals
 HSMN NewsFeed - 7 Jun 2007
Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 5 Jun 2007
Barr Announces Tentative Approval for a Generic Version of Risperdal(R) Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 4 Jun 2007
New Data on Market-Leading VELCADE(R) (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapy Substantially Improves Event-Free Survival and Complete Response Rate in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin's Lymphoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2007
Swiss Regulatory Authority Grants Accelerated Assessment of Planned Market Authorization Application for Ceftobiprole
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 May 2007
U.S. FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 11 May 2007
Barr Receives Tentative Approval for a Generic Version of Razadyne(R) Tablets, 4mg, 8mg and 12mg
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 27 Apr 2007
FDA Approves INVEGA (TM) for Long-Term Maintenance Treatment of Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Apr 2007
INVEGA(R) Receives Positive Opinion From European Committee for Human Medicinal Products for Treatment of Schizophrenia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Apr 2007
Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 24 Apr 2007
Neuromed Licenses Phase 3 Chronic Pain Product from ALZA Corporation
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 17 Apr 2007
Millennium Discovers Biomarkers Potentially Predictive of Response to VELCADE(R) (Bortezomib) for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Apr 2007
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Apr 2007
Elan Announces Board of Director Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Apr 2007
Angiotech appoints Chris Dennis as Senior Vice President, Sales and Marketing
Devices Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Mar 2007
Study Suggests INVEGA(TM) Helps Patients With Schizophrenia Maintain Symptom Control
Biopharmaceuticals
 HSMN NewsFeed - 26 Mar 2007
European Union CHMP Recommends Approval of First and Only Biologic Treatment for Pediatric Crohn's Disease: REMICADE(R)
Biopharmaceuticals Regulatory Gastroenterology
 HSMN NewsFeed - 5 Mar 2007
Alkermes Announces Senior Management Succession Plan
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Mar 2007
FDA Grants Pediatric Exclusivity for RISPERDAL(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Feb 2007
Basilea Reports Positive Phase III Results for Alitretinoin
Biopharmaceuticals
 HSMN NewsFeed - 16 Feb 2007
Anti-HIV Medication PREZISTA(TM) Receives Conditional Marketing Authorisation in the European Union
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 15 Feb 2007
Labopharm appoints Vice President Sales and Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jan 2007
Ortho Biotech Seeks FDA Approval for DOXIL(R) in Combination with VELCADE(R) to Treat Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Jan 2007
Alkermes and Lilly Expand AIR(R) Inhaled Insulin Collaboration
Biopharmaceuticals Endocrinology Drug Delivery Licensing
 HSMN NewsFeed - 8 Jan 2007
Panacos Appoints Alan W. Dunton, M.D. as New CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jan 2007
Alkermes and Indevus Announce Joint Collaboration to Develop Inhaled Formulation of Trospium Chloride for the Treatment of COPD
Biopharmaceuticals
 HSMN NewsFeed - 20 Dec 2006
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Dec 2006
INVEGA(TM) Approved By FDA as New Treatment for Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Dec 2006
Dr. Bob Tepper, President of R&D, to Leave Millennium
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Dec 2006
VELCADE(R) (bortezomib) for Injection Incorporated Into NCCN(R) Clinical Practice Guidelines for Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Positive Results from Combination Trials Build on VELCADE(R) (Bortezomib) for Injection Proven Single-Agent Strength in Relapsed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Multiple Myeloma Patients Respond to Retreatment with VELCADE(R) (Bortezomib) for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2006
VELCADE(R) (Bortezomib) for Injection Combination Shows High Complete and Near Complete Response Rate in Preliminary Data From Phase III Front-Line Multiple Myeloma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2006
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Dec 2006
Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Nov 2006
Janssen, L.P. Selects INVEGA(TM) (paliperidone) Extended Release tablets as Brand Name for Its Investigational Atypical Antipsychotic
Biopharmaceuticals
 HSMN NewsFeed - 26 Oct 2006
Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Oct 2006
Targacept Announces Addition of Alan W. Dunton, M.D. to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Oct 2006
U.S. District Court Upholds RISPERDAL(R) Patent
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 12 Oct 2006
Teva Announces Tentative Approval for Generic Risperdal(R) Oral Solution
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 6 Oct 2006
FDA Approves RISPERDAL(R) for Treatment of Irritability Associated with Autistic Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Oct 2006
Journal of Clinical Oncology Publishes Final Study Results of VELCADE(R) (Bortezomib) for Injection in Relapsed Mantle Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Sep 2006
FDA Issues Approvable Letter for Paliperidone ER for the Treatment of Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Sep 2006
Basilea Reports Excellent Pivotal Data for Ceftobiprole, a Novel Anti-MRSA Broad-spectrum Investigational Antibiotic, at ICAAC
Biopharmaceuticals
 HSMN NewsFeed - 28 Sep 2006
Tibotec Therapeutics Announces Initiation of the Largest U.S. Clinical Study Examining HIV Treatment in Treatment-Experienced Adult Women
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 26 Sep 2006
Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 Jul 2006
Barr Confirms Patent Challenge of Razadyne(R) ER Capsules
Biopharmaceuticals Litigation
 HSMN NewsFeed - 6 Jul 2006
Eisai Inc. Announces Appointment of Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jul 2006
MGI PHARMA Announces License Agreement with Cilag GmbH, a Johnson & Johnson Company, for Dacogen(TM) (decitabine) for Injection
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 30 Jun 2006
Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, Form Collaboration to Develop and Commercialize VX-950 for Treatment of Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 1 Jun 2006
Avid RP Strengthens Its Drug and Business Development Capabilities with the Addition of Three Industry Veterans
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 May 2006
New Analysis Showed Ulcerative Colitis Patients in Clinical Remission Had Higher Rates of Employment and Lower Rates of Disability
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 May 2006
Clinical Study of Investigational Drug Paliperidone ER Demonstrated Efficacy and Tolerability in the Treatment of Patients With Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
ALZA Corporation Receives FDA Approval for IONSYS(TM) (Fentanyl Iontophoretic Transdermal System)
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 16 May 2006
Wyeth Announces New Head of Corporate Diversity Effort
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 May 2006
Genitope Corporation Appoints Dr. Mary Rybak Vice President of Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 May 2006
Janssen-Cilag Submits Marketing Authorization Application in Europe for New Treatment for Schizophrenia
Biopharmaceuticals Drug Delivery
Return to NewsFeed  

 Additional items found! 150

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 150 additional stories matching:
Janssen
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.